SG11202007222RA - Antibody purification - Google Patents
Antibody purificationInfo
- Publication number
- SG11202007222RA SG11202007222RA SG11202007222RA SG11202007222RA SG11202007222RA SG 11202007222R A SG11202007222R A SG 11202007222RA SG 11202007222R A SG11202007222R A SG 11202007222RA SG 11202007222R A SG11202007222R A SG 11202007222RA SG 11202007222R A SG11202007222R A SG 11202007222RA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody purification
- antibody
- purification
- Prior art date
Links
- 238000011091 antibody purification Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862635943P | 2018-02-27 | 2018-02-27 | |
PCT/IB2019/051498 WO2019166932A1 (en) | 2018-02-27 | 2019-02-25 | Antibody purification |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007222RA true SG11202007222RA (en) | 2020-09-29 |
Family
ID=66049355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007222RA SG11202007222RA (en) | 2018-02-27 | 2019-02-25 | Antibody purification |
Country Status (13)
Country | Link |
---|---|
US (2) | US20210017254A1 (zh) |
EP (1) | EP3759134A1 (zh) |
JP (2) | JP7449041B2 (zh) |
KR (2) | KR20240067985A (zh) |
CN (1) | CN111788222A (zh) |
AU (2) | AU2019228377B2 (zh) |
BR (1) | BR112020015603A2 (zh) |
CA (1) | CA3034795A1 (zh) |
IL (1) | IL276816A (zh) |
MX (1) | MX2020008931A (zh) |
SG (1) | SG11202007222RA (zh) |
TW (1) | TWI839347B (zh) |
WO (1) | WO2019166932A1 (zh) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4205938A1 (de) * | 1992-02-27 | 1993-09-02 | Medac Klinische Spezialpraep | Immunotoxine |
PT1678208E (pt) * | 2003-10-27 | 2013-07-10 | Wyeth Llc | Remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatite |
WO2009017491A1 (en) * | 2006-06-14 | 2009-02-05 | Smithkline Beecham Corporation | Methods for purifying antibodies using ceramic hydroxyapatite |
EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
CN105473612A (zh) * | 2013-08-19 | 2016-04-06 | 豪夫迈·罗氏有限公司 | 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物 |
US20180142038A1 (en) * | 2015-01-16 | 2018-05-24 | ALDER BIOPHARMACEUTICALS, INC. a/b/a ALDERBIO HOLDINGS LLC | Anti-glycoprotein antibodies and uses thereof |
DK3283106T3 (da) * | 2015-04-13 | 2022-01-10 | Pfizer | Terapeutiske antistoffer og anvendelser deraf |
TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
BR112018003127A2 (pt) * | 2015-08-20 | 2018-09-25 | Genentech Inc | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes |
PE20191846A1 (es) | 2017-06-02 | 2019-12-31 | Pfizer | Anticuerpos especificos para flt3 y sus usos |
-
2019
- 2019-02-25 CA CA3034795A patent/CA3034795A1/en active Pending
- 2019-02-25 WO PCT/IB2019/051498 patent/WO2019166932A1/en unknown
- 2019-02-25 BR BR112020015603-5A patent/BR112020015603A2/pt unknown
- 2019-02-25 US US16/975,994 patent/US20210017254A1/en not_active Abandoned
- 2019-02-25 EP EP19715983.3A patent/EP3759134A1/en active Pending
- 2019-02-25 JP JP2019031207A patent/JP7449041B2/ja active Active
- 2019-02-25 TW TW108106273A patent/TWI839347B/zh active
- 2019-02-25 AU AU2019228377A patent/AU2019228377B2/en active Active
- 2019-02-25 MX MX2020008931A patent/MX2020008931A/es unknown
- 2019-02-25 SG SG11202007222RA patent/SG11202007222RA/en unknown
- 2019-02-25 CN CN201980015892.3A patent/CN111788222A/zh active Pending
- 2019-02-25 KR KR1020247015175A patent/KR20240067985A/ko active Application Filing
- 2019-02-25 KR KR1020207024435A patent/KR102665277B1/ko active IP Right Grant
-
2020
- 2020-08-19 IL IL276816A patent/IL276816A/en unknown
-
2023
- 2023-05-22 AU AU2023203205A patent/AU2023203205A1/en active Pending
- 2023-12-21 US US18/393,420 patent/US20240158473A1/en active Pending
-
2024
- 2024-02-06 JP JP2024016166A patent/JP2024042088A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019166932A1 (en) | 2019-09-06 |
TW201936644A (zh) | 2019-09-16 |
KR102665277B1 (ko) | 2024-05-13 |
CN111788222A (zh) | 2020-10-16 |
TWI839347B (zh) | 2024-04-21 |
AU2019228377B2 (en) | 2023-02-23 |
BR112020015603A2 (pt) | 2021-01-05 |
KR20200115569A (ko) | 2020-10-07 |
KR20240067985A (ko) | 2024-05-17 |
JP2024042088A (ja) | 2024-03-27 |
IL276816A (en) | 2020-10-29 |
JP7449041B2 (ja) | 2024-03-13 |
AU2019228377A1 (en) | 2020-08-20 |
MX2020008931A (es) | 2020-10-01 |
US20210017254A1 (en) | 2021-01-21 |
RU2020128326A (ru) | 2022-03-28 |
EP3759134A1 (en) | 2021-01-06 |
CA3034795A1 (en) | 2019-08-27 |
JP2019147793A (ja) | 2019-09-05 |
RU2020128326A3 (zh) | 2022-03-28 |
AU2023203205A1 (en) | 2023-06-15 |
US20240158473A1 (en) | 2024-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279321A (en) | Anti-SIRPalpha antibody | |
SG11202106214YA (en) | Novel anti-ccr8 antibody | |
IL280780A (en) | Anti-TIGIT antibodies | |
IL279352A (en) | IL-11RA antibodies | |
IL280013A (en) | Anti-IL36R antibodies | |
IL278010A (en) | Antibodies to galectin 10 | |
IL277030A (en) | Antibodies | |
GB202110263D0 (en) | Anti-btla antibodies | |
ZA202101177B (en) | Anti-btla antibody | |
GB201811368D0 (en) | Antibody | |
SG11202107474RA (en) | Anti-tigit antibodies | |
IL280140A (en) | Antigen purification method | |
IL281594A (en) | Antibodies against KLRG1 | |
ZA202108836B (en) | Anti-epha4 antibody | |
GB201817172D0 (en) | Antibody | |
EP4083211A4 (en) | ANTI-CDCP1 ANTIBODIES | |
GB201905150D0 (en) | Ant-ige antibodies | |
GB201806084D0 (en) | Antibodies | |
GB201900732D0 (en) | Antibodies | |
IL276816A (en) | Antibody purification | |
SG11202105718TA (en) | Modified antibodies | |
GB201919062D0 (en) | Antibody | |
GB201813597D0 (en) | Antibody | |
GB201912008D0 (en) | Antibody | |
GB201819952D0 (en) | Antibodies |